EUVIMEDEUVIMED entdecken
Studienprotokoll

Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study

Valentino Conter iD, Maria Grazia Valsecchi iD, Gunnar Cario, Martin Zimmermann iD, Andishe Attarbaschi iD, Jan Stary iD, Felix Niggli iD, Luciano Dalla Pozza, Sarah Elitzur iD, Daniela Silvestri, Franco Locatelli iD, Anja Möricke und 17 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01388 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Valentino Conter und 28 weiteren Autor:innen. Beteiligte Einrichtung: Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. Hauptthemen laut MEDLINE: Asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The AIEOP-BFM ALL 2009 protocol included, at the end of the induction phase, a randomized study of patients with high-risk (HR) ALL to investigate if an intensive exposure to pegylated L-asparaginase (PEG-ASNASE, 2,500 IU/sqm once a week × 4) on top of BFM consolidation phase IB allowed us to decrease minimal residual disease (MRD) and improve outcome. PATIENTS AND METHODS A total of 1,097 patients presented, from June 2010 to February 2017, with one or more of the following HR criteria: KMT2A::AFF1 rearrangement, hypodiploidy, prednisone poor response, poor bone marrow response at day 15 (Flow MRD ≥10%), or no complete remission (CR) at the end of induction. Of them, 809 (85.1%) were randomly assigned to receive (404) or not receive (405) four weekly doses of PEG-ASNASE. RESULTS By intention to treat (ITT) analysis, there was no significant difference in the proportion of patients with polimerase chain reaction MRD ≥5 × 10 −4 at the end of phase IB in the experimental versus control arm (13.9% v 17.0%, P = .25). The 5-year event-free survival (median follow-up 6.3 years) by ITT in the experimental and control arms was 70.4% (2.3) versus 75.0% (2.2; P = .18), and the 5-year overall survival was 81.5% (2.0) versus 84.0% (1.9; P = .25), respectively. The corresponding 5-year cumulative incidence of death in CR was 9.5% (1.5) versus 5.7% (1.2; P = .08), and that of relapse was 17.7% (1.9) versus 17.2% (1.9), respectively ( P = .94). Adverse reactions in phase IB occurred in 22.2% and 8.9% of patients in the experimental and control arm, respectively ( P < .001). CONCLUSION Additional PEG-ASNASE in phase IB did not translate into a benefit for decreasing relapse incidence but was associated with higher toxicity. Further improvements with conventional chemotherapy might be difficult in the context of intensive treatment protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsparaginasePrecursor Cell Lymphoblastic Leukemia-LymphomaHumansInfantPrednisoneTreatment OutcomeDisease-Free SurvivalNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsPolyethylene GlycolsRecurrenceRandomized Controlled Trials as Topic

Substanzen

AsparaginasePrednisonePolyethylene Glycols

Autor:innen und Institutionen

  • Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Department of Pediatrics I, Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany.
  • Department of Pediatric Hematology and Oncology, St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Valentino Conter, Maria Grazia Valsecchi, Martin Zimmermann, Andishe Attarbaschi, Jan Stary, Felix Niggli, Sarah Elitzur, Franco Locatelli, Petr Smisek, Shai Izraeli, Carmelo Rizzari, Barbara Buldini, Massimo Zucchetti, Cristina Matteo, Thomas Lehrnbecher, Giovanni Cazzaniga, Andrea Biondi, Martin Schrappe

Zitieren

APA

Conter, V., Valsecchi, M. G., Cario, G., Zimmermann, M., Attarbaschi, A., Stary, J., Niggli, F., Dalla Pozza, L., Elitzur, S., Silvestri, D., Locatelli, F., Möricke, A., Engstler, G., Smisek, P., Bodmer, N., Barbaric, D., Izraeli, S., Rizzari, C., Boos, J., …, & Schrappe, M. (2024). Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01388

Vancouver

Conter V, Valsecchi MG, Cario G, Zimmermann M, Attarbaschi A, Stary J, et al. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01388

BibTeX
@article{Conter2024,
  author = {Conter, Valentino and Valsecchi, Maria Grazia and Cario, Gunnar and Zimmermann, Martin and Attarbaschi, Andishe and Stary, Jan and Niggli, Felix and Dalla Pozza, Luciano and Elitzur, Sarah and Silvestri, Daniela and Locatelli, Franco and Möricke, Anja and Engstler, Gernot and Smisek, Petr and Bodmer, Nicole and Barbaric, Draga and Izraeli, Shai and Rizzari, Carmelo and Boos, Joachim and Buldini, Barbara and Zucchetti, Massimo and von Stackelberg, Arend and Matteo, Cristina and Lehrnbecher, Thomas and Lanvers-Kaminsky, Claudia and Cazzaniga, Giovanni and Gruhn, Bernd and Biondi, Andrea and Schrappe, Martin},
  title = {Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01388}
}
Kostenlos starten →